The latest price target for BeiGene (NASDAQ:BGNE) was reported by TD Cowen on November 13, 2024. The analyst firm set a price target for $260.00 expecting BGNE to rise to within 12 months (a possible 33.63% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for BeiGene (NASDAQ:BGNE) was provided by TD Cowen, and BeiGene maintained their buy rating.

The last upgrade for BeiGene Ltd happened on October 13, 2022 when Guggenheim raised their price target to $205. Guggenheim previously had a neutral for BeiGene Ltd.

The last downgrade for BeiGene Ltd happened on June 30, 2023 when Bernstein changed their price target from $335 to $196 for BeiGene Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BeiGene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BeiGene was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.

While ratings are subjective and will change, the latest BeiGene (BGNE) rating was a maintained with a price target of $254.00 to $260.00. The current price BeiGene (BGNE) is trading at is $194.56, which is out of the analyst’s predicted range.